Price without Sales data is 22-28$/share in 2012. Price w.Sales data in 2014 likely to be over 35-60$/share.
By the way, Pfizer and Astra Zeneca are looking at Vascepa right now.They prefer marketing agreement with rights to acquire within 15 months.
But these negotiations are unpredictable.Who will win- will be clear within 2 months?
Streetinsider gives you ratings and price targets for all the analysts based on the data and projections and DCF analysis-give them 21.50 to 28$/share targets.
35-60$/share is based on FDA approval for 200-500mg trigl. population in July-Aug.2013,initial data of Sales for Vascepa-wide range on how fast Vascepa grows.
60$/share is based on Lipitor Sales in 1997-98 similarity and Reduce-IT trials progress.
Since we won't have full results until 2015 or 2016-- advertising claims will be monitored by FDA in USA.
Pfizer as well as Astra Zeneca are top marketers--Pfizer took Lipitor to 10 bil.$ sales and AZN took Crestor to 6 bil.$ sales/year.
Both PFE and AZN have wide gap--Pfizer now,AZN in 2016 with patents expiring.Example: Lipitor Generic is offered by WEGMAN's for FREE. Yes FREE-- We bought it.
So PFE is hurting. The question is price they would pay now vs.pay after they see Sales data?